Latest news and video coverage curated from trusted media outlets
Equity indices trade higher, pharma stocks rally
Credit: ANI Duration: 01:24Published
Equity indices nudge lower on weak global cues, banking stocks dip
Credit: ANI Duration: 01:09Published
Closing bell: Equity indices in positive terrain, Dr Reddy's top gainer
Credit: ANI Duration: 01:21Published
Russian Direct investment fund partners with Dr. Reddy's for Sputnik V trials in India|Oneindia News
Credit: Oneindia Duration: 01:03Published
Equity indices spurt with rally in banking scrips, IndusInd up 12 pc
Credit: ANI Duration: 01:13Published
Equity indices dip on weak global cues, pharma stocks hit
Credit: ANI Duration: 01:11Published
Equity indices close in the green, Cipla gains 9.5 pc
Credit: ANI Duration: 01:17Published
Equity indices gain 1% on global cues, metal stocks shine
Credit: ANI Duration: 01:04Published
You Might Like
DRL launches generic of PrecedexDr. Reddy’s has unveiled Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Hospira’s Preced
Mitesh Thakkar: BUY TCS, Dr Reddy’s; SELL Axis Bank and BPCL
India trials for Russia's 'Sputnik-V' vaccine could start in next few weeksIndian trials of the Sputnik-V vaccine candidate, being developed by Russia`s sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals..
Also reported by •IndiaTimes
The Hindu Explains | What do we know about Russia’s COVID-19 vaccine candidate Sputnik V?How will the tie-up with Dr. Reddy’s Laboratories help India?
Equity indices close lower on profit booking, Dr Reddy's up 10 pc
Dr Reddy’s shares extend rally; zoom over 10%On the NSE, it zoomed 9.92% to close at ₹ 5,306.
DRL, Celgene settle Revlimid patent suitPharma major Dr. Reddy’s Laboratories and Celgene, a wholly owned subsidiary of Bristol Myers Squibb, have settled their litigation relating to patent
COVID-19 vaccine to be available in India by early 2021: Union Health Minister Harsh VardhanMeanwhile, Russia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of the world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's Laboratories as Moscow speeds..
COVID-19 vaccination to be available by 'start of next year': Harsh VardhanUnion Health Minister Harsh Vardhan on Thursday said that the coronavirus vaccine will be made available in the country by the start of next year. The remarks come at a time when India is recording..
Russia, Dr Reddy’s tie up for Sputnik V trialRussia’s sovereign wealth fund – Russian Direct Investment Fund (RDIF) — has partnered Hyderabad-based drug maker Dr Reddy’s Laboratories to cooperate on clinical trials and distribution of..
Dr Reddy’s inks deal to distribute 100 mn doses of Sputnik V
Russia inks pact to test, supply Sputnik V vaccine to IndiaAgreement with Dr. Reddy’s Laboratories doesn’t include its manufacture.
Russia confirms deal with Dr. Reddy's for COVID-19 vaccine 'Sputnik V' trials in India, to supply 100 million dosesRussia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's Laboratories as Moscow speeds up plans to..
Russia to sell 100 million doses of Covid-19 vaccine to IndiaRussia's sovereign wealth fund said on Wednesday it will supply India's Dr Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against Covid-19 once it receives regulatory approval...
Also reported by •newKerala.com •Mid-Day
Equity indices in positive terrain, Dr Reddy's top gainer
DRL prices Remdesivir at ₹5,400 a vialDr. Reddy’s Laboratories has unveiled Gilead Sciences’ Remdesivir, an investigational drug used in COVID-19 treatment, under the Redyx brand in India
Dr Reddy's launches Remdesivir in IndiaPharma major Dr Reddy’s Laboratories Ltd on Wednesday announced the rollout of potential Covid-19 treatment generic drug Remdesivir, under the Redyx brand name in India. Dr Reddy’s has announced..
Also reported by •Hindu